Table 2 Data about the influenza vaccination from 2009 to 2019 in Belgium
|  | ’09–’10 seasonal vaccine | ’09–’10 Pandemrix vaccine | ’10– ‘11 | ’11– ‘12 | ’12–‘13 | ’13–‘14 | ’14–‘15 | ’15–‘16 | ’16–‘17 | ’17–‘18 | ’18–‘19 | Mean [SD] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Composition | A/Brisbane/59/2007 | A/California/7/2009 | A/California/7/2009 | “ | “ | “ | “ | “ | “ | A/Michigan/45/2015 | “ |  |
 A(H1N1)pdm09 |  | AS03 |  |  |  |  |  |  |  |  |  |  |
 A(H3N2) | A/Brisbane/10/2007 | / | A/Perth/16/2009 | “ | A/Victoria/361/2011 | A/Texas/50/2012 | “ | A/Switzerland/971529/2013 | A/Hong-Kong/4801/2014 | “ | A/Singapore/INFIMH-16–0019/2016 |  |
 B | B/Brisbane/60/2008a | / | “ | “ | B/Wisconsin/1/2010b | B/Massachusetts/2/2012b | “ | B/Phuket/3073/2013b | B/Brisbane/60/2008a | “ | B/Colorado/06/2017a |  |
 Quadrivalent | / | / | / | / | / | / | / | B/Brisbane/60/2008a | B/Phuket/3073/2013b | “ | “ |  |
Effectiveness (%) | / | / | Moderate to high | Low to moderate | 47 | 55 | 19 | 41 | 28c | 41 | 13 | 34.9 [15.3] |
Antiviral resistance | Yesd | / | No | / | No | Yesd | No | Yesd | No | No | Yes | Â |